Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Academic Radiology|November 4, 2025
The METAL Score for Early Stratification of Radiological Response and Survival in Hepatocellular Carcinoma Treated with TACE and Immunotherapy CombinationsQian Chen, Long-Wang Lin, Zhi-Cheng Jin, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|August 29, 2025
A Novel Self-Regulated, Non-Directional Magnetic Thermos-Brachytherapy 125I Seed Enhances Anticancer Efficacy by Rescuing Immune EscapeBin Xu, Ye-Ming Wu, Yi-Fei Cheng, et al.
Alimentary Pharmacology & Therapeutics|March 31, 2026
Camrelizumab and Apatinib With or Without Transarterial Chemoembolisation as First-Line Treatment for Advanced Hepatocellular Carcinoma (CHANCE2311)Rong Ding, Jin-Feng Bai, Zhi-Cheng Jin, et al.
Eclinicalmedicine|February 18, 2026
Transarterial chemoembolization (TACE) combined with immunotherapy and anti-angiogenic agents in intermediate-stage hepatocellular carcinoma (CHANCE2202): a target trial emulation studyJian-Jian Chen, Zhi-Cheng Jin, Jia-Wei Zhou, et al.
Hepatology (Baltimore, Md.)|November 10, 2025
Decoding tumor heterogeneity with imaging biomarkers predicts response to TACE plus immunotherapy and targeted therapy in HCC (CHANCE2204)Zhi-Cheng Jin, Jingwei Wei, Yu-Dong Xiao, et al.
Journal of Cachexia, Sarcopenia and Muscle|November 27, 2024
Longitudinal Body Composition Identifies Hepatocellular Carcinoma With Cachexia Following Combined Immunotherapy and Target Therapy (CHANCE2213)Zhi-Cheng Jin, Jia-Wei Zhou, Jian-Jian Chen, et al.
Eclinicalmedicine|May 15, 2024
Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation studyZhi-Cheng Jin, Jian-Jian Chen, Xiao-Li Zhu, et al.
Signal Transduction and Targeted Therapy|February 8, 2023
Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001)Hai-Dong Zhu, Hai-Liang Li, Ming-Sheng Huang, et al.
Pageof 2